Impact of renin-angiotensin system inhibitors on mortality
during the COVID Pandemic among STEMI patients undergoing
mechanical reperfusion: Insight from an international STEMI
registry

J 2021

Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry

DE LUCA, G., M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC et. al.

Základní údaje

Originální název

Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry

Autoři

DE LUCA, G. (garant), M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC, T. JOHNSON, M. G. BLANCAS, V. GANYUKOV, W. WOJAKOWSKI, C. VON BIRGELEN, A. IJSSELMUIDEN, B. TUCCILLO, F. VERSACI, J. T. BERG, M. LAINE, T. BERKOUT, G. CASELLA, Petr KALA (203 Česká republika, domácí), B. L. LEDESMA, V. BECERRA, R. PADALINO, A. SANTUCCI, X. CARRILLO, A. SCOCCIA, G. AMOROSO, A. L. T. KOVARNIK, P. DAVLOUROS, G. GABRIELLI, X. F. RIOS, N. BAKRACESKI, S. LEVESQUE, V. GUIDUCCI, M. KIDAWA, L. MARINUCCI, F. ZILIO, G. GALASSO, E. FABRIS, M. MENICHELLI, S. MANZO, G. CAIAZZO, J. MOREU, J. S. FOR, L. DONAZZAN, L. VIGNALI, R. TELES, P. AGOSTONI, F. B. OJEDA, H. LEHTOLA, S. CAMACHO-FREIERE, A. KRAAIJEVELD, Y. ANTTI, G. VISCONTI, I. L. MARTINEZ-LUENGAS, B. SCHELLER, D. ALEXOPULOS, R. MORENO, E. KEDHI, G. UCCELLO, B. FAURIE, A. G. BARRIOS, F. S. DI UCCIO, B. WILBERT, G. CORTESE, M. T. DIRKSEN, G. PARODI a M. VERDOIA

Vydání

BIOMEDICINE & PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0753-3322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.419

Kód RIV

RIV/00216224:14110/21:00123838

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.biopha.2021.111469

UT WoS

000641397100006

Klíčová slova anglicky

Renin-Angiotensin System inhibitors; ST-segment elevation myocardial infarction; Mortality; COVID-19; Percutaneous coronary intervention

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 1. 2022 10:18, Mgr. Tereza Miškechová

Anotace

V originále

Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51-0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33-0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084-0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect. Conclusions: This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.

Citovat

DE LUCA, G., M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC, T. JOHNSON, M. G. BLANCAS, V. GANYUKOV, W. WOJAKOWSKI, C. VON BIRGELEN, A. IJSSELMUIDEN, B. TUCCILLO, F. VERSACI, J. T. BERG, M. LAINE, T. BERKOUT, G. CASELLA, Petr KALA, B. L. LEDESMA, V. BECERRA, R. PADALINO, A. SANTUCCI, X. CARRILLO, A. SCOCCIA, G. AMOROSO, A. L. T. KOVARNIK, P. DAVLOUROS, G. GABRIELLI, X. F. RIOS, N. BAKRACESKI, S. LEVESQUE, V. GUIDUCCI, M. KIDAWA, L. MARINUCCI, F. ZILIO, G. GALASSO, E. FABRIS, M. MENICHELLI, S. MANZO, G. CAIAZZO, J. MOREU, J. S. FOR, L. DONAZZAN, L. VIGNALI, R. TELES, P. AGOSTONI, F. B. OJEDA, H. LEHTOLA, S. CAMACHO-FREIERE, A. KRAAIJEVELD, Y. ANTTI, G. VISCONTI, I. L. MARTINEZ-LUENGAS, B. SCHELLER, D. ALEXOPULOS, R. MORENO, E. KEDHI, G. UCCELLO, B. FAURIE, A. G. BARRIOS, F. S. DI UCCIO, B. WILBERT, G. CORTESE, M. T. DIRKSEN, G. PARODI a M. VERDOIA. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, roč. 138, June 2021, s. 1-7. ISSN 0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2021.111469.

@article{1823859,
   author = {De Luca, G. and Cercek, M. and Jensen, L. O. and Bushljetikj, O. and Calmac, L. and Johnson, T. and Blancas, M. G. and Ganyukov, V. and Wojakowski, W. and von Birgelen, C. and IJsselmuiden, A. and Tuccillo, B. and Versaci, F. and Berg, J. T. and Laine, M. and Berkout, T. and Casella, G. and Kala, Petr and Ledesma, B. L. and Becerra, V. and Padalino, R. and Santucci, A. and Carrillo, X. and Scoccia, A. and Amoroso, G. and Kovarnik, A. L. T. and Davlouros, P. and Gabrielli, G. and Rios, X. F. and Bakraceski, N. and Levesque, S. and Guiducci, V. and Kidawa, M. and Marinucci, L. and Zilio, F. and Galasso, G. and Fabris, E. and Menichelli, M. and Manzo, S. and Caiazzo, G. and Moreu, J. and For, J. S. and Donazzan, L. and Vignali, L. and Teles, R. and Agostoni, P. and Ojeda, F. B. and Lehtola, H. and CamachoandFreiere, S. and Kraaijeveld, A. and Antti, Y. and Visconti, G. and MartinezandLuengas, I. L. and Scheller, B. and Alexopulos, D. and Moreno, R. and Kedhi, E. and Uccello, G. and Faurie, B. and Barrios, A. G. and Di Uccio, F. S. and Wilbert, B. and Cortese, G. and Dirksen, M. T. and Parodi, G. and Verdoia, M.},
   article_location = {Paris},
   article_number = {June 2021},
   doi = {http://dx.doi.org/10.1016/j.biopha.2021.111469},
   keywords = {Renin-Angiotensin System inhibitors; ST-segment elevation myocardial infarction; Mortality; COVID-19; Percutaneous coronary intervention},
   language = {eng},
   issn = {0753-3322},
   journal = {BIOMEDICINE & PHARMACOTHERAPY},
   title = {Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry},
   url = {https://www.sciencedirect.com/science/article/pii/S0753332221002547?via%3Dihub},
   volume = {138},
   year = {2021}
}

TY  - JOUR
ID  - 1823859
AU  - De Luca, G. - Cercek, M. - Jensen, L. O. - Bushljetikj, O. - Calmac, L. - Johnson, T. - Blancas, M. G. - Ganyukov, V. - Wojakowski, W. - von Birgelen, C. - IJsselmuiden, A. - Tuccillo, B. - Versaci, F. - Berg, J. T. - Laine, M. - Berkout, T. - Casella, G. - Kala, Petr - Ledesma, B. L. - Becerra, V. - Padalino, R. - Santucci, A. - Carrillo, X. - Scoccia, A. - Amoroso, G. - Kovarnik, A. L. T. - Davlouros, P. - Gabrielli, G. - Rios, X. F. - Bakraceski, N. - Levesque, S. - Guiducci, V. - Kidawa, M. - Marinucci, L. - Zilio, F. - Galasso, G. - Fabris, E. - Menichelli, M. - Manzo, S. - Caiazzo, G. - Moreu, J. - For, J. S. - Donazzan, L. - Vignali, L. - Teles, R. - Agostoni, P. - Ojeda, F. B. - Lehtola, H. - Camacho-Freiere, S. - Kraaijeveld, A. - Antti, Y. - Visconti, G. - Martinez-Luengas, I. L. - Scheller, B. - Alexopulos, D. - Moreno, R. - Kedhi, E. - Uccello, G. - Faurie, B. - Barrios, A. G. - Di Uccio, F. S. - Wilbert, B. - Cortese, G. - Dirksen, M. T. - Parodi, G. - Verdoia, M.
PY  - 2021
TI  - Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
JF  - BIOMEDICINE & PHARMACOTHERAPY
VL  - 138
IS  - June 2021
SP  - 1-7
EP  - 1-7
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN  - 07533322
KW  - Renin-Angiotensin System inhibitors
KW  - ST-segment elevation myocardial infarction
KW  - Mortality
KW  - COVID-19
KW  - Percutaneous coronary intervention
UR  - https://www.sciencedirect.com/science/article/pii/S0753332221002547?via%3Dihub
N2  - Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51-0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33-0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084-0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect. Conclusions: This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.
ER  -

DE LUCA, G., M. CERCEK, L. O. JENSEN, O. BUSHLJETIKJ, L. CALMAC, T. JOHNSON, M. G. BLANCAS, V. GANYUKOV, W. WOJAKOWSKI, C. VON BIRGELEN, A. IJSSELMUIDEN, B. TUCCILLO, F. VERSACI, J. T. BERG, M. LAINE, T. BERKOUT, G. CASELLA, Petr KALA, B. L. LEDESMA, V. BECERRA, R. PADALINO, A. SANTUCCI, X. CARRILLO, A. SCOCCIA, G. AMOROSO, A. L. T. KOVARNIK, P. DAVLOUROS, G. GABRIELLI, X. F. RIOS, N. BAKRACESKI, S. LEVESQUE, V. GUIDUCCI, M. KIDAWA, L. MARINUCCI, F. ZILIO, G. GALASSO, E. FABRIS, M. MENICHELLI, S. MANZO, G. CAIAZZO, J. MOREU, J. S. FOR, L. DONAZZAN, L. VIGNALI, R. TELES, P. AGOSTONI, F. B. OJEDA, H. LEHTOLA, S. CAMACHO-FREIERE, A. KRAAIJEVELD, Y. ANTTI, G. VISCONTI, I. L. MARTINEZ-LUENGAS, B. SCHELLER, D. ALEXOPULOS, R. MORENO, E. KEDHI, G. UCCELLO, B. FAURIE, A. G. BARRIOS, F. S. DI UCCIO, B. WILBERT, G. CORTESE, M. T. DIRKSEN, G. PARODI a M. VERDOIA. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. \textit{BIOMEDICINE \&{} PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, roč.~138, June 2021, s.~1-7. ISSN~0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2021.111469.

Podrobný výpis o publikaci